
CRO Solutions for Metabolic & Cardiovascular Diseases
Cyagen offers comprehensive CRO solutions to accelerate your research in metabolic and cardiovascular diseases. From diverse, validated disease models to robust in vivo and in vitro platforms, we provide end-to-end support, guiding your projects seamlessly from early discovery to IND application. Partner with us to advance your therapeutic breakthroughs.
One-Stop Metabolic & Cardiovascular Diseases CRO Solutions
Explore Cyagen’s integrated preclinical solutions for metabolic and cardiovascular
diseases, covering obesity, diabetes, dyslipidemia, hypertension, liver and kidney disorders, and
atherosclerosis. We offer a robust library of validated models, advanced in vivo efficacy platforms, and in
vitro mechanism studies – all designed to support your translational research and drug development needs.
{{ item.title }}
{{static_tabs[0].title}}
Standard Models
At Cyagen, we provide a solid foundation for your ophthalmic research with over 20 validated
humanized and genetic models targeting common ocular diseases such as glaucoma, macular
degeneration, and diabetic retinopathy. We also specialize in creating custom animal models,
including knockout, knockin, and humanized models, tailored to meet the specific needs of your
studies.
Base Strain
Search for Models
Catalog Number | Name | Base Strain | Research Application | Action |
---|---|---|---|---|
{{ value.product_num || "--" }} | {{ value.product_name || "--" }} | {{ value.product_strain || "--" }} |
{{v2}};
|
|
Next Page
Custom Induction-Based Models
In addition to our genetic model library, Cyagen offers a collection of
induction-based models developed through established experimental protocols. While not currently
listed in MouseAtlas™, these models are validated and available through our custom services.
These models are ideal for studies requiring clinical-like disease phenotypes
that cannot be fully recapitulated by gene-edited lines alone.
Available Models Include:
- NASH / MASH: HFD + CCl₄-induced fatty liver injury
- Alcoholic Steatohepatitis
- Acute & Chronic Liver Injury (CCl₄)
- DIO Obesity & Type 2 Diabetes Models
- Diabetic Complications Models
- Renal Disease Models
- Pulmonary Arterial Hypertension (PAH)
- Peripheral Vascular Disease / Stroke Models
Looking for a custom disease model not listed in our database?
Our scientific team can develop or adapt models to fit your study requirements.
Request a Custom Model
Consultation >>
{{static_tabs[1].title}}
Our in vivo CRO platform delivers customized efficacy evaluation for metabolic and
cardiovascular drugs. From glucose tolerance and lipid profiling to liver and vascular pathology, we
help generate data aligned with clinical endpoints.
Obesity & Diabetes Models
- Body weight, food intake, GTT/ITT, fasting/random blood glucose, metabolic cage analysis
- Histological analysis (H&E, Oil Red O, Sirius Red, IHC)
Liver & Pancreas Evaluation
- Hepatic weight, enzyme markers (ALT/AST), tissue volume quantification
- Pancreatic edema, saponification spot observation in acute pancreatitis models
Kidney Function Studies
- Urine volume/protein/sugar, GFR, inflammatory cytokines (TGF-β1, IL-6), BUN, CRE
- Histopathology and biomarker-based renal injury assessment
Atherosclerosis & Cardiovascular Evaluation
- Blood lipids (HDL-C, LDL-C, TG, TC), aortic plaque area quantification
- Oil Red O, H&E staining of aortic arch
Looking for tailored in vivo assays to validate your candidate?
{{static_tabs[2].title}}
Our in vitro platform offers robust target validation and mechanism-of-action
studies using primary cells and functional assays tailored to metabolic and cardiovascular diseases.
Target-Based Drug Screening
- PPAR-α/γ, 11β-HSD, GLP-1R, PCSK9, DPP-IV, and Factor Xa assays
Biomarker Profiling
- Adipokines and hormones: Leptin, GIP, GLP1, Resistin, Ghrelin, etc.
- Cytokines: multiplex detection (MSD, Luminex, ELISA)
Cellular Models for MOA Research
- INS-1, MIN6, HK-2, primary hepatocytes, mesangial cells, and adipocyte models
- Glucose transporter uptake and cAMP signaling studies
Need support for in vitro screening or mechanistic insights?
Case Examples
{{ item.label }}
{{v2.label}}
{{item.context}}
{{v2.context}}
{{item.title}}
{{ item.context }}
Our Unique Advantages
Broad Model Coverage with Clinical Relevance
From classic ob/ob and Apoe KO models to inducible MASH and PAH systems, our platform supports both genetic and induction-based disease models to match diverse drug discovery needs.
Integrated In Vivo & In Vitro Evaluation Systems
Our end-to-end services cover behavioral testing, blood biochemistry, histology, molecular assays, and target engagement studies—empowering complete pharmacodynamic insights in metabolic and cardiovascular indications.
Proven Experience in Translational Research
With 200+ successful projects and validated data for IND-enabling studies, we provide reliable support for preclinical efficacy assessment and customized model development for metabolic and cardiovascular drug pipelines.
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.